{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:52:57Z","timestamp":1772725977198,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in the treatment of COVID-19 are highly debated. This study was\u00a0aimed to assess aggregated risk by investigating the association of ACEIs\/ARBs users against non-users of ACEIs\/ARBs with the risk of mortality or severe clinical manifestations or magnitude of SARS-CoV-2 test positivity in COVID-19 patients. Systematic literature search was carried out in different databases for eligible studies. The pooled relative risks (RRs) were measured using RevMan software where <jats:italic>P<\/jats:italic>&lt;0.05 was set as statistical significance. In total, 10 studies were included in this analysis. After pooled estimation, it was demonstrated that SARS-CoV-2 positive patients taking ACEIs\/ARBs were not associated with an increased risk of mortality compared to those not taking ACEIs\/ARBs (RR 0.89; 95% CI 0.64\u20131.23; <jats:italic>P<\/jats:italic>=0.48). Furthermore, the risk of composite severe clinical manifestations was not significantly different between the positive patients with or without ACEIs\/ARBs users (RR 1.29; 95% CI 0.81\u20132.04; <jats:italic>P<\/jats:italic>=0.28). There was no risk difference for SARS-CoV-2 test positivity in patients with or without ACEIs\/ARBs users (RR 1.00; 95% CI 0.95\u20131.05; <jats:italic>P<\/jats:italic>=0.91). These findings may augment current professional society guidelines for not discontinuing ACEIs\/ARBs in treating COVID-19 patients where it is clinically indicated.<\/jats:p>","DOI":"10.1038\/s41598-021-84678-9","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T11:02:36Z","timestamp":1614769356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-7701","authenticated-orcid":false,"given":"Mohitosh","family":"Biswas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3363-0303","authenticated-orcid":false,"given":"Most. Sumaiya Khatun","family":"Kali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"84678_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1855","author":"N Mehta","year":"2020","unstructured":"Mehta, N. et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.1855 (2020).","journal-title":"JAMA Cardiol."},{"key":"84678_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2019.20153","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA J. Am. Med. Assoc. 323, 1824\u20131836 (2020).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"84678_CR3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","volume":"43","author":"Y Ishiyama","year":"2004","unstructured":"Ishiyama, Y. et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43, 970\u2013976 (2004).","journal-title":"Hypertension"},{"key":"84678_CR4","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario, C. M. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605\u20132610 (2005).","journal-title":"Circulation"},{"key":"84678_CR5","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan, M. et al. Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19. N. Engl. J. Med. 382, 1653\u20131659 (2020).","journal-title":"N. Engl. J. Med."},{"key":"84678_CR6","doi-asserted-by":"publisher","unstructured":"Biswas, M., Rahaman, S., Biswas, T. K., Haque, Z. & Ibrahim, B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: A systematic review and meta-analysis. Intervirology. 9, 1\u201312. https:\/\/doi.org\/10.1159\/000512592 (2020).","DOI":"10.1159\/000512592"},{"key":"84678_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648","author":"Z Wu","year":"2020","unstructured":"Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the chinese center for disease control and prevention. JAMA J. Am. Med. Assoc. https:\/\/doi.org\/10.1001\/jama.2020.2648 (2020).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"84678_CR8","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang, L., Karakiulakis, G. & Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir. Med. 8, e21 (2020).","journal-title":"Lancet Respir. Med."},{"key":"84678_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21656","author":"D Gurwitz","year":"2020","unstructured":"Gurwitz, D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev. Res. https:\/\/doi.org\/10.1002\/ddr.21656 (2020).","journal-title":"Drug Dev. Res."},{"key":"84678_CR10","doi-asserted-by":"publisher","first-page":"104927","DOI":"10.1016\/j.phrs.2020.104927","volume":"158","author":"X Zhang","year":"2020","unstructured":"Zhang, X., Yu, J., Pan, L.-Y. & Jiang, H.-Y. ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis. Pharmacol. Res. 158, 104927 (2020).","journal-title":"Pharmacol. Res."},{"key":"84678_CR11","doi-asserted-by":"publisher","DOI":"10.7326\/m20-1515","author":"K Mackey","year":"2020","unstructured":"Mackey, K. et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann. Intern. Med. https:\/\/doi.org\/10.7326\/m20-1515 (2020).","journal-title":"Ann. Intern. Med."},{"key":"84678_CR12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0445OC","author":"Y Feng","year":"2020","unstructured":"Feng, Y. et al. COVID-19 with different severity: a multi-center study of clinical features. Am. J. Respir. Crit. Care Med. https:\/\/doi.org\/10.1164\/rccm.202002-0445OC (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"84678_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1624","author":"J Li","year":"2020","unstructured":"Li, J., Wang, X., Chen, J., Zhang, H. & Deng, A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan China. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.1624 (2020).","journal-title":"JAMA Cardiol."},{"key":"84678_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2007621","author":"MR Mehra","year":"2020","unstructured":"Mehra, M. R., Desai, S. S., Kuy, S., Henry, T. D. & Patel, A. N. Cardiovascular disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2007621 (2020).","journal-title":"N. Engl. J. Med."},{"key":"84678_CR15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng, J. et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg. Microbes Infect. 9, 757\u2013760 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"84678_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2008975","author":"HR Reynolds","year":"2020","unstructured":"Reynolds, H. R. et al. Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of Covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2008975 (2020).","journal-title":"N. Engl. J. Med."},{"key":"84678_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775","author":"S Richardson","year":"2020","unstructured":"Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized With COVID-19 in the New York City Area. JAMA J. Am. Med. Assoc. https:\/\/doi.org\/10.1001\/jama.2020.6775 (2020).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"84678_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1017","author":"T Guo","year":"2020","unstructured":"Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.1017 (2020).","journal-title":"JAMA Cardiol."},{"key":"84678_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","author":"G Yang","year":"2020","unstructured":"Yang, G. et al. Effects Of ARBs And ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study. Hypertension https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15143 (2020).","journal-title":"Hypertension"},{"key":"84678_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.120.317134","author":"P Zhang","year":"2020","unstructured":"Zhang, P. et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ. Res. https:\/\/doi.org\/10.1161\/circresaha.120.317134 (2020).","journal-title":"Circ. Res."},{"key":"84678_CR21","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.2147\/IDR.S264882","volume":"13","author":"AS Yehualashet","year":"2020","unstructured":"Yehualashet, A. S. & Belachew, T. F. ACEIs and ARBs and their correlation with COVID-19: a review. Infect. Drug Resist. 13, 3217\u20133224 (2020).","journal-title":"Infect. Drug Resist."},{"key":"84678_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 63, 364\u2013374 (2020).","journal-title":"Sci. China Life Sci."},{"key":"84678_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30566-3","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet https:\/\/doi.org\/10.1016\/s0140-6736(20)30566-3 (2020).","journal-title":"Lancet"},{"key":"84678_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.0950","author":"S Shi","year":"2020","unstructured":"Shi, S. et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan China. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.0950 (2020).","journal-title":"JAMA Cardiol."},{"key":"84678_CR25","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan, W. et al. Clinical characteristics of 2019 novel coronavirus infection in China. N. Engl. J. Med. 382, 1708\u20131720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"84678_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05991-x","author":"Q Ruan","year":"2020","unstructured":"Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan China. Int. Car. Med. https:\/\/doi.org\/10.1007\/s00134-020-05991-x (2020).","journal-title":"Int. Car. Med."},{"key":"84678_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4326","author":"M Arentz","year":"2020","unstructured":"Arentz, M. et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. JAMA J. Am. Med. Assoc. https:\/\/doi.org\/10.1001\/jama.2020.4326 (2020).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"84678_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China. JAMA J. Am. Med. Assoc. 323, 1061\u20131069 (2020).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"84678_CR29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923","author":"G Mancia","year":"2020","unstructured":"Mancia, G., Rea, F., Ludergnani, M. & Apolone, G. Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2006923 (2020).","journal-title":"N. Engl. J. Med."},{"key":"84678_CR30","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.eclinm.2020.100404","volume":"23","author":"D Pan","year":"2020","unstructured":"Pan, D. et al. The impact of ethnicity on clinical outcomes in COVID-19: a systematic review. EClinicalMedicine 23, 100404 (2020).","journal-title":"EClinicalMedicine"},{"key":"84678_CR31","doi-asserted-by":"crossref","unstructured":"Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J. & Welch, V. A. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Handbook (2020). https:\/\/training.cochrane.org\/cochrane-handbook-systematic-reviews-interventions.","DOI":"10.1002\/9781119536604"},{"key":"84678_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 5, 210 (2016).","journal-title":"Syst. Rev."},{"key":"84678_CR33","unstructured":"Wells, G., Shea, B., O\u2019Connell, D. & Peterson, J. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (2000)."},{"key":"84678_CR34","doi-asserted-by":"publisher","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","volume":"127","author":"J Lau","year":"1997","unstructured":"Lau, J., Ioannidis, J. P. A. & Schmid, C. H. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127, 820\u2013826 (1997).","journal-title":"Ann. Intern. Med."},{"key":"84678_CR35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. Br. Med. J. 327, 557\u2013560 (2003).","journal-title":"Br. Med. J."},{"key":"84678_CR36","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1136\/bmj.320.7249.1574","volume":"320","author":"AJ Sutton","year":"2000","unstructured":"Sutton, A. J., Duval, S. J., Tweedie, R. L., Abrams, K. R. & Jones, D. R. Empirical assessment of effect of publication bias on meta-analyses. Br. Med. J. 320, 1574\u20131577 (2000).","journal-title":"Br. Med. J."},{"key":"84678_CR37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 315, 629\u2013634 (1997).","journal-title":"Br. Med. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84678-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84678-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84678-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:25:18Z","timestamp":1670041518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84678-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["84678"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-84678-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"22 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5012"}}